MAPK3 and colorectal carcinoma: To further study the interactions between the ERK1/2 and ERK5 pathways, we used human colorectal cancer (CRC) cell lines HCT116 and DLD-1 that harbour heterozygous KRASG13D (gain-of-function) mutations.